Zydus Lifesciences said its subsidiary had acquired US-based BridgeBio Pharma. Sentynl Therapeutics, a subsidiary of Zydus Lifesciences and BridgeBio Pharma, have done an asset purchase agreement for the sale of Nulibry (Fosdenopterin) for injection. The product is approved by the Food and Drug Administration (FDA) to decrease the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, which is a life-threatening paediatric genetic disorder. Under the terms of the agreement, Sentynl will be liable for the ongoing development and commercialisation of Nulibry in the US and developing, manufacturing and commercialising it globally, Zydus Lifesciences said in a statement.

BridgeBio will share development responsibilities for Fosdenopterin via approval of the marketing authorisation application under accelerated assessment with the European Medicines Agency and its regulatory submission with the Israeli Ministry of Health. Sentynl will also give cash payments on the achievement of regulatory milestones. BridgeBio will be eligible to receive commercial milestone payments and tiered royalties on adjusted net sales of Nulibry, it added.